Plus Therapeutics (PSTV) Interest Coverage Ratio (2011 - 2026)
Plus Therapeutics (PSTV) reported Interest Coverage Ratio of 418.76 for Q1 2026, down 6389.91% year-over-year from 6.66 in Q1 2025, and down 6389.91% quarter-over-quarter from 6.45 in Q1 2025.
Plus Therapeutics (PSTV) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 16 years of Interest Coverage Ratio data on file, last reported at 418.76 in Q1 2026.
- Interest Coverage Ratio for Q1 2026 came in at 418.76, down 6389.91% year-over-year; the trailing twelve-month figure through Mar 2026 was 1110.65 (down 5054.56% YoY), and the FY2025 annual result was 27.92, up 66.0% from the prior year.
- Interest Coverage Ratio declined to 418.76 in Q1 2026 per PSTV's latest filing, from 6.45 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 6.45 in Q1 2025 and troughed at 418.76 in Q1 2026.
- A 5-year average of 75.84 and a median of 43.78 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2025 and 2026: Interest Coverage Ratio jumped 93.35% in 2025, then slumped 6389.91% in 2026.
- A 5-year view of Interest Coverage Ratio shows it stood at 50.2 in 2022, then declined by 23.96% to 62.23 in 2023, then fell by 9.96% to 68.42 in 2024, then soared by 90.57% to 6.45 in 2025, then tumbled by 6389.91% to 418.76 in 2026.
- Business Quant data shows PSTV's Interest Coverage Ratio at 418.76 in Q1 2026, 6.45 in Q1 2025, and 68.42 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -258.33 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 11.79 |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - | -418.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -418.76 |
| Mar 31, 2025 | -6.45 |
| Dec 31, 2024 | -68.42 |
| Sep 30, 2024 | -62.28 |
| Jun 30, 2024 | -136.93 |
| Mar 31, 2024 | -97.03 |
| Dec 31, 2023 | -62.23 |
| Sep 30, 2023 | -37.37 |
| Jun 30, 2023 | -13.30 |
| Mar 31, 2023 | -35.24 |
| Dec 31, 2022 | -50.20 |
| Sep 30, 2022 | -25.47 |
| Jun 30, 2022 | -28.29 |
| Mar 31, 2022 | -19.83 |
| Dec 31, 2021 | -20.52 |
| Sep 30, 2021 | -17.50 |
| Jun 30, 2021 | -12.88 |
| Mar 31, 2021 | -10.04 |
| Dec 31, 2020 | -16.98 |
| Sep 30, 2020 | -4.65 |